CRISPR Therapeutics AG (CRISPR Therapeutics AG) Earnings per Share (Diluted) : $-1.93 (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG Earnings per Share (Diluted)?

CRISPR Therapeutics AG's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $1.13. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.93.

CRISPR Therapeutics AG's EPS (Basic) for the three months ended in Dec. 2023 was $1.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.93.

CRISPR Therapeutics AG's EPS without NRI for the three months ended in Dec. 2023 was $1.13. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.93.

During the past 3 years, the average EPS without NRIGrowth Rate was 28.40% per year.

During the past 10 years, CRISPR Therapeutics AG's highest 3-Year average EPS without NRI Growth Rate was 28.40% per year. The lowest was -94.60% per year. And the median was -51.55% per year.

CRISPR Therapeutics AG Earnings per Share (Diluted) Historical Data

The historical data trend for CRISPR Therapeutics AG's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Earnings per Share (Diluted) Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

1.17

-5.29

4.70

-8.36

-1.94

CRISPR Therapeutics AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-1.41	-0.67	-0.98	-1.41	1.13

Competitive Comparison of CRISPR Therapeutics AG's Earnings per Share (Diluted)

For the Biotechnology subindustry, CRISPR Therapeutics AG's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CRISPR Therapeutics AG's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's PE Ratio distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's PE Ratio falls into.

CRISPR Therapeutics AG Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

CRISPR Therapeutics AG's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-153.61	-	0)	/	79.221
	=	-1.94

CRISPR Therapeutics AG's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(89.347	-	0)	/	79.693
	=	1.12

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.93

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

CRISPR Therapeutics AG (NAS:CRSP) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

CRISPR Therapeutics AG Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

CRSP:Mexico

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Executives

Samarth Kulkarni	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Raju Prasad	officer: Chief Financial Officer	CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127
Phuong Khanh Morrow	officer: Chief Medical Officer	C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139
Maria Fardis	director	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Brendan Smith	officer: Chief Financial Officer	29 HARTWELL AVENUE, LEXINGTON MA 02421
Michael John Tomsicek	officer: Chief Financial Officer	28 OVERLOOK DRIVE, BEDFORD MA 01730
Bolzon Bradley J Phd	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Rodger Novak	director, officer: Chief Executive Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Harold Edward Fleming	director	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Lawrence Otto Klein	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139
James R. Kasinger	officer: General Counsel and Secretary	C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139
Tony W Ho	officer: See Remarks	CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Douglas A Treco	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Pablo J Cagnoni	director	ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Katherine A High	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104